Bellerophon recently announced promising results in a trial assessing INOpulse, its investigational treatment device for pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). Results showed the device led to an average increase in exercise capacity by the end of the four-week trial and a decrease in lung artery blood pressure.
News
Tracleer (bosentan) has become the first therapy to obtain U.S. regulatory approval for treating pulmonary hypertension in children. The Food and Drug Administration authorized it for children aged 3 and older who have idiopathic or congenital pulmonary arterial hypertension (PAH). Actelion Pharmaceuticals, the company that holds the marketing license for…
Beta blockers, the cornerstone therapy for left-side heart failure, can improve pulmonary arterial hypertension, a small study indicates. The results suggested that the therapy could help prevent right-side heart failure, the leading cause of death among PAH patients. The study, “Pulmonary arterial hypertension treatment with carvedilol for…
The U.S. Food and Drug Administration (FDA) has declined SteadyMed Therapeutics‘ new drug application (NDA) for its Trevyent (treprostinil injection) therapy to treat pulmonary arterial hypertension (PAH). SteadyMed, with offices in San Ramon, California, and in Israel, had submitted its NDA in July 2017. But the application was denied on Aug. 31…
Three ongoing clinical trials are recruiting additional participants to allow for more robust assessments of Reata Pharmaceuticals’ bardoxolone methyl therapy as a potential treatment for various forms of pulmonary hypertension. Two of the trials — the Phase 3 CATALYST (NCT02657356) trial, which examines…
The use of Revatio (sildenafil) to treat pulmonary hypertension in patients with valvular heart disease leads to worse clinical outcomes compared to placebo, results from a new clinical trial indicate. Results from the Phase 4 SIOVAC trial (NCT00862043) were presented at a Hot Line Late Breaking Clinical Trials (LBCT)…
Actelion’s Uptravi (selexipag) delays the progression of pulmonary arterial hypertension that stems from connective tissue disease, a follow-up analysis of Phase 3 clinical trial findings indicates. People with PAH-CTD also tolerate the therapy fairly well, according to the study. The PAH part of PAH-CTD refers to high blood pressure…
African-Americans with pulmonary hypertension and without health insurance have a two-fold increased risk of dying of this disease compared to white Americans, possibly because of delays in referral and treatment, a retrospective study reports. The study “Health Insurance and Racial Disparities in Pulmonary Hypertension Outcomes,” published in…
Arena Pharmaceuticals will present new information in Barcelona this weekend on its pulmonary hypertension therapy ralinepag, which a clinical trial showed improved patients’ heart blood vessel resistance and exercise capacity. The two presentations at the European Society of Cardiology Congress, Aug. 26-30, will focus on the results of preclinical-trial studies in rats and…
Ventripoint Diagnostics‘ VMS Heart Analysis System, which produces a two-dimensional (2D) volumetric reconstruction model of the heart, accurately measures small changes in the heart’s right ventricle volume and can be used in patients with pulmonary hypertension (PH), a new study finds. The study, “Two-dimensional knowledge-based volumetric reconstruction of the…
Estrogen inhibitors may treat pulmonary vascular disease by correcting metabolic defects in women with pulmonary arterial hypertension (PAH), say researchers at Nashville’s Vanderbilt University. Their study,“Oestrogen inhibition reverses pulmonary arterial hypertension and associated metabolic defects,” appeared in the European Respiratory Journal. Most people with hereditary PAH have mutations…
Adcirca (tadalafil) exerts a variety of positive effects that may explain why the therapy improves idiopathic pulmonary arterial hypertension (IPAH), according to an in vitro study. The study, “Tadalafil induces antiproliferation, apoptosis, and phosphodiesterase type 5 downregulation in idiopathic pulmonary arterial hypertension in vitro,” was published…
